Publication:
One Virus, Two Diseases: Evaluation of Clinical and Immunological Differences in COVID-19 and Multisystem Inflammatory Syndrome Cases

dc.authorwosidErdeniz, Emine Hafize/Aaa-2249-2022
dc.authorwosidKökcü Karadağ, Şefika/Kwu-8048-2024
dc.contributor.authorKaradag, Sefika Ilknur Kokcu
dc.contributor.authorErdeniz, Emine Hafize
dc.contributor.authorOzkan, Esra
dc.contributor.authorYildiran, Alisan
dc.date.accessioned2025-12-11T00:44:00Z
dc.date.issued2024
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Karadag, Sefika Ilknur Kokcu; Yildiran, Alisan] Ondokuz Mayis Univ, Dept Pediat Allergy & Immunol, Fac Med, Samsun, Turkiye; [Erdeniz, Emine Hafize] Ondokuz Mayis Univ, Fac Med, Dept Pediat Infect, Samsun, Turkiye; [Ozkan, Esra] Ondokuz Mayis Univ, Dept Pediat Child Emergency, Fac Med, Samsun, Turkiyeen_US
dc.description.abstractObjectives: This study aims to uncover early detection markers through the immunological analysis of children diagnosed with multisystem inflammatory syndrome (MIS -C) and coronavirus disease -2019 (COVID-19). Methods: We retrospectively analyzed immunological data from thirty-three MIS-C patients and an equivalent number of patients under the age of 18 with a positive polymerase chain reaction (PCR) test for COVID-19. These individuals were admitted to Ondokuz Mayis University between November 2020 and February 2021. In total, the study group consisted of 66 patients and an additional 10 healthy controls. Results: Lymphopenia, thrombocytopenia, anemia, and neutrophilia, along with elevated levels of ferritin, D-dimer, and C -reactive protein, were more pronounced in MIS-C patients (p<0.001). No significant disparities were found in serum IgG, A, M, and E concentrations. Notably, there was an increased proportion of B cells (p<0.001), an inversion of the CD4/CD8 ratio, and a marked presence of CD3+CD38+HLA-DR+active T cells (p=0.009) in the MIS-C cohort. Conclusion: In the early diagnosis of MIS-C, lymphopenia, increase in B cells, reversal of CD4/CD8 ratio, and demonstration of CD3+CD38+HLA-DR+active T cells may be helpful.en_US
dc.description.woscitationindexEmerging Sources Citation Index
dc.identifier.doi10.14744/SEMB.2023.23316
dc.identifier.endpage90en_US
dc.identifier.issn1302-7123
dc.identifier.issn1308-5123
dc.identifier.issue1en_US
dc.identifier.pmid38808056
dc.identifier.startpage82en_US
dc.identifier.trdizinid1332590
dc.identifier.urihttps://doi.org/10.14744/SEMB.2023.23316
dc.identifier.urihttps://search.trdizin.gov.tr/en/yayin/detay/1332590/one-virus-two-diseases-evaluation-of-clinical-and-immunological-differences-in-covid-19-and-multisystem-inflammatory-syndrome-cases
dc.identifier.urihttps://hdl.handle.net/20.500.12712/38853
dc.identifier.volume58en_US
dc.identifier.wosWOS:001201790900002
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofMedical Bulletin of Sisli Etfal Hospitalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChilden_US
dc.subjectCOVID-19en_US
dc.subjectImmunologyen_US
dc.subjectMultisystem Inflammatory Syndromeen_US
dc.titleOne Virus, Two Diseases: Evaluation of Clinical and Immunological Differences in COVID-19 and Multisystem Inflammatory Syndrome Casesen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files